ARCHIVES

After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA

This article is from The Cancer Letter archive.

Vol. 21 No. 15 | April 14, 1995

Download PDF Visit The Full Archive

Related Articles

Treanda Approved For B-Cell Non-Hodgkin’s Lymphoma

October 31, 2008

DCT Board Approves Contract Recompetitions Worth 44.8 Million In First Year Awards

November 5, 1982

Breast Cancer Coalition Widens Its Agenda For Advocacy, Vows To Fight NIH Cutbacks

May 5, 1995

Kennedy Chooses Health/Education Chair Over Judiciary; No Major Changes In Senate Cancer Policies Expected

November 14, 1986

Vidaza For MDS Approved; sNDAs for Taxotere, Gemzar

May 28, 2004

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005